Connect with us

Company News

Long-suffering GE shareholders flex muscle on pay

Executive pay often resembles a ratchet, only going in one direction: up. Shareholders of General Electric on Tuesday rebelled. Nearly 58% of them voted against top executives’ pay for 2020, including $73 million for boss Larry Culp. It’s a rare rebuke, richly deserved.

A long-term investor in GE may see cause for hope. The shares are down a third over 10 years, against a roughly 200% gain in the S&P 500 Index. In the past year, though, they’ve beaten the benchmark. Culp has slimmed down the conglomerate since assuming the chief executive role in 2018. He sold a biopharma unit for $21 billion, divested lightbulbs, reduced the firm’s stake in oil-services company Baker Hughes , and agreed to merge GE’s aircraft-leasing business with specialist AerCap .

But Culp has not yet put GE’s decades of trouble behind it. And investors took umbrage at last August’s repricing of some of the “inducement” granted to him when he started. The original grant would have paid him well over $200 million if GE’s stock price hit $31. The new package has the same potential payout, but with a new upper trigger of $16.68 per share, barely more than half the old. Though any of those big stock awards are several years away, that fattened up his reported pay for last year, giving a hollow ring to the pandemic-year gesture of giving up his bonus and most of his salary.

Rewarding executives for raising a company’s stock price is supposed to put them on the same side as shareholders. Changing the hurdle downward after a company’s stock hits a bad patch undoes that alignment. Some stock-market hits aren’t a CEO’s fault. Even so, while investors have to grit their teeth and bear losses, the already handsomely paid executive simply gets a reset.

Say-on-pay votes, as they are known, are advisory, not binding. But majority votes against a board’s judgment are rare and can’t be ignored. AT&T also got the thumbs-down on Friday, and shareholders have already balked at compensation at a few other public companies during the current annual-meeting season. If they keep this up, perhaps boards of directors will at least use their ratchets more sparingly. Reuters

Copyright © 2024 Medical Buyer

error: Content is protected !!